$0.20 EPS Expected for Corcept Therapeutics Incorporated (CORT) as of May, 7

April 16, 2018 - By Arnold Ferreira

Corcept Therapeutics Incorporated (NASDAQ:CORT) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.49. That’s change of 0.47, from 2017Q3’s 1.96. 30 investors sold all, 42 reduced holdings as Corcept Therapeutics Incorporated ratio dived. 67 grew positions while 40 funds acquired positions. Funds hold 87.40 million shares thus 21.46% more from 2017Q3’s 71.96 million shares.
Profund Advsr Lc, a Maryland-based fund reported 14,217 shs. Engineers Gate Manager Lp has 85,654 shs for 0.11% of their capital. 78,310 were reported by Comml Bank Of Montreal Can. Ny State Teachers Retirement owns 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 38,319 shs. Catalyst Capital Advsrs Limited Liability Corporation owns 0.05% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 67,900 shs. Louisiana State Employees Retirement Sys owns 40,800 shs. Arizona State Retirement reported 133,708 shs. Mckinley Cap Management Limited Liability Corp Delaware accumulated 0.28% or 308,823 shs. Georgia-based Invesco Limited has invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Credit Suisse Ag holds 0% of its capital in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 117,506 shs. Acadian Asset Management Ltd accumulated 2.48 million shs. Impact Advisors Lc accumulated 0.61% or 78,194 shs. Hillsdale Mgmt Inc has 90,300 shs. Cubist Systematic Strategies Limited Liability Corp invested 0.02% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Robeco Institutional Asset Mngmt Bv invested 0% of its capital in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Corcept Therapeutics Incorporated had 5 selling transactions and 1 insider buy since December 8, 2017. This’s net activity of $515,904. Another trade for 10,000 shs valued at $155,102 was bought by GALA RENEE D.

Corcept Therapeutics Incorporated (NASDAQ:CORT)’s earnings report is expected On May, 7., RTT reports. The earnings per share diference is $0.16 or 400.00 % up from last years number. Previous year: $0.04; Analysts forcast: $0.20. CORT’s profit could hit $22.97 million if the current earnings per share of $0.20 is accurate. Last quarter $0.17 earnings per share was reported. Analysts sees 17.65 % EPS growth this quarter. On during the last trading session the stock increased $0.113 or 0.67%, reaching $17.093.Currently Corcept Therapeutics Incorporated is uptrending after 52.11% change in last April 16, 2017. CORT has 325,057 shares volume. The stock outperformed the S&P 500 by 40.56%.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Ratings Coverage

In total 4 analysts cover Corcept Therapeutics Inc (NASDAQ:CORT). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 5 are the (NASDAQ:CORT)’s analyst reports since November 3, 2017 according to StockzIntelligence Inc. On Friday, November 3 the rating was maintained by Stifel Nicolaus with “Buy”. On Thursday, March 8 the stock has “Buy” rating by FBR Capital. The stock rating was maintained by FBR Capital with “Buy” on Tuesday, March 20. The stock rating was initiated by Seaport Global with “Buy” on Friday, April 13.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.The firm is worth $1.96 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.16.44 is the P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: